Skin immune system

Cancer Treatment and Research

Volumn 146, Issue , 2009, Pages 45-62

  Bos, Jan D ^a   Luiten, Rosalie M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; MELANOMA ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CARCINOMA; CELL MATURATION; CELL POPULATION; CELLULAR IMMUNITY; DENDRITIC CELL; DNA REPAIR; ENDOTHELIUM CELL; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; KERATINOCYTE; LANGERHANS CELL; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REVIEW; SKIN CANCER; SKIN FUNCTION; SPINOCELLULAR CARCINOMA; SUN EXPOSURE; T LYMPHOCYTE; TUMOR VIRUS; ANIMAL; BIOLOGICAL MODEL; IMMUNE SYSTEM; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; INFLAMMATION; METABOLISM; MOUSE; ORGAN TRANSPLANTATION; PHENOTYPE; PROCEDURES; SKIN;

ADAPTIVE IMMUNITY; ANIMALS; HUMANS; IMMUNE SYSTEM; INFLAMMATION; MICE; MODELS, BIOLOGICAL; MONITORING, IMMUNOLOGIC; ONCOGENIC VIRUSES; ORGAN TRANSPLANTATION; PHENOTYPE; SKIN;

EID: 77953675053     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-78574-5_5     Document Type: Review

References (53)

1. Silverstein AM. A History of Immunology. San Diego: Academic Press, 1989.
2. Fichtelius KE, Groth O, Liden S. The skin, a first level lymphoid organ? Int Arch Allergy 1970; 37:607-20.
3. Streilein JW. Lymphocyte traffic, T cell malignancies and the skin. J Invest Dermatol 1978; 71:167-71.
4. Streilein JW. Skin-associated lymphoid tissues (SALT): the next generation. In: Bos JD (ed) Skin Immune System (SIS), 1st edn. Boca Raton: CRC Press, 1990:25-48.
5. Vroom ThA, Bos JD, Borst J. Epithelial homing of gamma/delta T cells? Nature 1989; 341:113-4.
6. Bos JD, Teunissen MBM, Cairo I, Krieg SR, Kapsenberg ML, Das PK, Borst J. T cell receptor gamma/delta bearing cells in normal human skin. J Invest Dermatol 1990; 94:37-42.
7. Bos JD, Kapsenberg ML. The skin immune system (SIS): its cellular constituents and their interactions. Immunol Today 1986; 7:235-40.
8. Bos JD (ed) Skin Immune System (SIS), 1st edn. Boca Raton: CRC Press, 1990.
9. Bos JD (ed) Skin Immune System (SIS): Cutaneous Immunology and Clinical Immunodermatology, 2nd edn. Boca Raton: CRC Press, 1997.
10. Bos JD (ed) Skin Immune System (SIS): Cutaneous Immunology and Clinical Immunodermatology, 3rd edn. Boca Raton: CRC Press, 2005.
11. Sontheimer RD. Perivascular dendritic macrophages as immunobiological constituents of the human dermal perivascular unit. J Invest Dermatol 1989; 93:96S-101S.
12. Nickoloff BJ (ed). Dermal Immune System. Boca Raton: CRC Press, 1993.
13. Teunissen MB, Piskin G, di Nuzzo S, Sylva-Steenland RM, de Rie MA, Bos JD. Ultraviolet B radiation induces a transient appearance of IL-4+ neutrophils, which support the development of Th2 responses. J Immunol 2002; 168:3732-9.
14. Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004; 4:211-22.
15. Asahina A, Tamaki K. Role of Langerhans cells in cutaneous protective immunity: Is the reappraisal necessary? J Dermatol Sci 2006; 44:1-9.
16. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52.
17. Clydesdale GJ, Dandie GW, Muller HK. Ultraviolet light induced injury: immunological and inflammatory effects. Immunol Cell Biol 2001; 79:547-68.
18. Xiao BG, Huang YM, Link H. Tolerogenic dendritic cells: the ins and outs of outcome. J Immunother 2006; 29:465-71.
19. Clark RA, Chong B, Mirchandani N, Brinster NK, Yamanaka K, Dowgiert RK, Kupper TS. The vast majority of CLA+ T cells are resident in normal skin. J Immunol 2006; 176:4431-9.
20. Bos JD, Zonneveld I, Das PK, Krieg SR, Van der Loos ChM, Kapsenberg ML. The skin immune system (SIS): distribution and immunophenotype of lymphocyte subpopulations in normal human skin. J Invest Dermatol 1987; 88:569-73.
21. Santamaria-Babi LF. CLA(+) T cells in cutaneous diseases. Eur J Dermatol 2004; 14:13-8.
22. Dudda JC, Simon JC, Martin S. Dendritic cell immunization route determines CD8+ T cell trafficking to inflamed skin: role for tissue microenvironment and dendritic cells in establishment of T cell-homing subsets. J Immunol 2004; 172:857-63.
23. Gutgesell C, Heise S, Seubert A, Stichtenoth DO, Fröhlich JC, Neumann C. Comparison of different activity parameters in atopic dermatitis: correlation with clinical scores. Br J Dermatol 2002; 147:914-9.
24. Dudley ME,Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers- Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-4.
25. Schadendorf D, Paschen A, Eichmüller S. Immunological strategies to fight skin cancer. In: Bos JD (ed) Skin Immune System (SIS): Cutaneous Immunology and Clinical Immunodermatology. Boca Raton: CRC Press, 2005:745-70.
26. Luiten RM, Kueter EW, Mooi W, Gallee MP, Rankin EM, Gerritsen WR, Clift SM, Nooijen WJ, Weder P, van de Kasteele WF, Sein J, van den Berk PC, Nieweg OE, Berns AM, Spits H, de Gast GC. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol 2005; 23:8978-91.
27. Ullrich SE, Kripke ML. Mechanisms in the suppression of tumor rejection produced in mice by repeated UV irradiation. J Immunol 1984; 133:2786-90.
28. Schwarz T. Regulatory T cells induced by ultraviolet radiation. Int Arch Allergy Immunol 2005; 137:187-93.
29. Stoebner PE, Rahmoun M, Ferrand C,Meunier L, Yssel H, Pene J. A single sub-erythematous exposure of solar-simulated radiation on the elicitation phase of contact hypersensitivity induces IL-10-producing T-regulatory cells in human skin. Exp Dermatol 2006; 15: 615-24.
30. Hoshida Y, Aozasa K.Malignancies in organ transplant recipients. Pathol Int 2004; 54:649-58.
31. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005; 80 (2 Suppl): S254-64.
32. Wilkins K, Turner R, Dolev JC, LeBoit PE, Berger TG, Maurer TA. Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol 2006; 54:189-206.
33. Muller HK, Halliday GM, Woods GM. The skin immune system and tumor immunosurveillance. In: Bos JD (ed) Skin Immune System (SIS): Cutaneous Immunology and Clinical Immunodermatology. Boca Raton: CRC Press, 2005:475-94.
34. Parmiani G. An explanation of the variable clinical response to interleukin 2 and LAK cells. Immunol Today 1990; 11:113-5.
35. Boon T, Coulie PG, Van den Eynde BJ, Van der Bruggen B. Human T cell responses against melanoma. Annu Rev Immunol 2006; 24:175-208.
36. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354:709-18.
37. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10:475-80.
38. Vermi W, Bonecchi R, Facchetti F, Bianchi D, Sozzani S, Festa S, Berenzi A, Cella M, Colonna M. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol 2003; 200:255-68.
39. de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Croockewit S, Britten CM, Torensma R, Adema GJ, Figdor CG, Punt CJ. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003; 9:5091-100.
40. van Mierlo GJ, Boonman ZF, Dumortier HM, den Boer AT, Fransen MF, Nouta J, van der Voort EI, Offringa R, Toes RE, Melief CJ. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J Immunol 2004; 173: 6753-9.
41. Furumoto K, Soares L, Engleman EG, Merad M. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest 2004; 113:774-83.
42. Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ, Kalinski P. Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 2004; 64:5934-7.
43. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6:715-27.
44. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388:190-5.
45. Medema JP, de Jong J, van Hall T, Melief CJ, Offringa R. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med 1999; 190:1033-8.
46. Ugurel S, Seiter S, Rappl G, Stark A, Tilgen W, Reinhold U. Heterogeneous susceptibility to CD95-induced apoptosis in melanoma cells correlates with bcl-2 and bcl-x expression and is sensitive to modulation by interferon-gamma. Int J Cancer 1999; 82:727-36.
47. Nachmias B, Ashhab Y, Bucholtz V, Drize O, Kadouri L, Lotem M, Peretz T, Mandelboim O, Ben Yehuda D. Caspase-mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: implications for drug-resistant melanoma. Cancer Res 2003; 63:6340-9.
48. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C, Lowe SW. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001; 409:207-11.
49. Lord SJ, Rajotte RV, Korbutt GS, Bleackley RC. Granzyme B: a natural born killer. Immunol Rev 2003; 193:31-8.
50. Bird CH, Sutton VR, Sun J, Hirst CE, Novak A, Kumar S, Trapani JA, Bird PI. Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway. Mol Cell Biol 1998; 18:6387-98.
51. Sun J, Bird CH, Sutton V, McDonald L, Coughlin PB, De Jong TA, Trapani JA, Bird PI. A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J Biol Chem 1996; 271:27802-9.
52. Medema JP, de Jong J, Peltenburg LT, Verdegaal EM, Gorter A, Bres SA, Franken KL, Hahne M, Albar JP, Melief CJ, Offringa R. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci U S A 2001; 98:11515-20.
53. Bos JD. Skin immune system (SIS). In: Bos JD (ed) Skin Immune System (SIS): Cutaneous Immunology and Clinical Immunodermatology. Boca Raton: CRC Press, 2005:3-17.